logo

For the Inventor, By the Inventor

Lausanne, Switzerland

Debiopharm International, S.a.


USPTO Granted Patents = 20



Trademarks = 8

Forward Citations = 30

Loading Chart...
Loading Chart...

48 inventors (with patents filed for the assignee):

goldMedal Jutta Deckert (6 out of 13 patents)

silverMedal Angela Romanelli (3 out of 3 patents)

bronzeMedal Daniel J Tavares (3 out of 53 patents)

4.  Lingyun Rui (3 out of 35 patents)

5.  Grégoire Vuagniaux (3 out of 8 patents)

6.  Peter U Park (3 out of 31 patents)

7.  Rodrigo R Ruiz-Soto (2 out of 4 patents)

8.  Jan Pinkas (2 out of 4 patents)

9.  Anthony Marfat (2 out of 62 patents)

10.  Heinz W Pauls (2 out of 44 patents)

11.  John Colucci (2 out of 23 patents)

12.  Helmi Zaghdane (2 out of 7 patents)

13.  Linda Kadi (2 out of 2 patents)

14.  Sélène Ferrari (2 out of 2 patents)

15.  Yves Gareau (2 out of 7 patents)


20 patents:

1. 12473283 - Compounds and their use (2025-11-18),
2. 12414958 - Medicament and use thereof for treating bacterial infections involving biofilm (2025-09-16),
3. 12403131 - Afabicin formulation, method for making the same and uses thereof (2025-09-02),
4. 12239732 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2025-03-04),
5. 12144818 - Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens (2024-11-19),
6. 11673140 - Sample collection and processing device (2023-06-13),
7. 11466095 - CD37-binding molecules and immunoconjugates thereof (2022-10-11),
8. 11395796 - Anti-CD37 immunoconjugate and anti-CD20 antibody combinations (2022-07-26),
9. 11278629 - Methods for improving anti-CD37 immunoconjugate therapy (2022-03-22),
10. 11104740 - Antibodies and assays for detection of CD37 (2021-08-31),
11. 10751351 - Medicament for treatment of diabetic foot infections (2020-08-25),
12. 10703798 - Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL) (2020-07-07),
13. 10589275 - Sample collection and processing device (2020-03-17),
14. 10556958 - CD37-binding molecules and immunoconjugates thereof (2020-02-11),
15. 10202460 - CD37-binding molecules and immunoconjugates thereof (2019-02-12),
Debiopharm International, S.A. is a global biopharmaceutical company specialized in the development and manufacturing of innovative prescription drugs. With a focus on oncology, immunology, and companion diagnostics, Debiopharm aims to provide personalized medicine solutions to improve patient outcomes. The company has a strong commitment to scientific research and development, leveraging collaborations and partnerships to advance cutting-edge therapies. With a presence in various countries, Debiopharm is dedicated to delivering impactful healthcare solutions worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

20 Patents

#17 in Lausanne

#594 in Switzerland

#30,346 in the World

...
Lausanne, Switzerland

Debiopharm International, S.a.

Forward Citations = 30

48 inventors:

goldMedal Jutta Deckert (6 out of 13 patents)

silverMedal Angela Romanelli (3 out of 3 patents)

bronzeMedal Daniel J Tavares (3 out of 53 patents)

4.  Lingyun Rui (3 out of 35 patents)

5.  Grégoire Vuagniaux (3 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…